ANDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Pharmacologic Class:
Macrolide Antimicrobial
Indications (11)
mild to moderate infections caused by susceptible isolates due to Haemophilus influenzaeMoraxella catarrhalisUsage ]Haemophilus parainfluenzaedevelopment of drug-resistant bacteriamaintain the effectiveness of clarithromycin extended-release tabletsother antibacterial drugsclarithromycin extended-release tablets should be used only to treatprevent infectionsstrongly suspected to be caused by bacteriastrongly suspected to be caused by susceptible bacteria
Clinical Trials (5)
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Started Mar 2025
26 enrolled
Healthy Adults
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
Started Jul 2023
22 enrolled
Healthy Volunteers
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
Started Nov 2022
35 enrolled
Safety IssuesPharmacokineticsDrug Interaction+1 more
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
Started Aug 2022
26 enrolled
Healthy
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
Started Dec 2021